projects
building a pause button for biological time ↗
In 2022, I dropped out of my PhD at Oxford to join the founding team of Until in San Francisco.Cryopreservation is already essential to modern medicine—powering IVF and life-saving stem cell therapies. Now, we are extending this technology to whole human organs — transforming hours of viability into weeks, or months, however long is necessary — so that no donated organ is lost to logistics, and no patient dies waiting.
helping students and researchers turn research into ventures ↗
I co-founded Edventure, a pan-European startup incubator helping students and researchers turn bold ideas into real ventures. As founding director, I built and ran programs across the UK and Europe — from early pilots to partnerships with universities and, ultimately, Cancer Research UK, helping scientists and oncologists turn breakthroughs in cancer research into companies that save lives.
creating europe's biggest-ever student entrepreneurship conference ↗
In University, I started and co-hosted organised Europe's biggest-ever student entrepreneurship conference, featuring 47 founders, leaders, and operators from leading organizations and more than a thousand attendees.
A podcast interviewing founders, investors and other interesting people.
innovating high-throughput drug discovery ↗
At Edinburgh Medical School, I designed and executed a high-throughput in vivo screen to evaluate 38 drug candidates for progressive multiple sclerosis (PMS) — a stage of the disease marked by neurodegeneration and currently lacking effective treatments. Using larval zebrafish, I assessed drug-induced toxicity across 18 physiological and morphological endpoints, generating over 23,000 datapoints. To overcome the interpretive bottlenecks of multi-endpoint screens, I developed a novel, modular toxicity index that captures cumulative, multidimensional toxicity as a single summary score — something existing indices (e.g. LD50 or LOADED) fail to do.
building a synthetically engineered biosensor for detection of water contaminants ↗
Representing the University of Edinburgh at iGEM, I co-developed a transcription-only, cell-free biosensing platform for rapid and cost-effective detection of water contaminants. Our system replaced conventional GFP reporters with fluorescent RNA aptamers and incorporated isothermal amplification and basic logic processing via synthetic RNA transcription bubbles and T7 RNA polymerase.
personalizing boutique publishing ↗
In high school (in Germany), my brother and I built an online platform that let users create fully personalized print magazines — choosing their own articles, themes, and even the cover. Think: Spotify playlist meets boutique publishing. We partnered with major media brands like DIE ZEIT, handling everything from licensing to layout automation and on-demand printing.
The product found a niche with consumers, corporate clients, and cultural institutions, and was acquired in 2017 by a German publishing house modernizing its print strategy.
building a pause button for biological time ↗
In 2022, I dropped out of my PhD at Oxford to join the founding team of Until in San Francisco.Cryopreservation is already essential to modern medicine—powering IVF and life-saving stem cell therapies.Now, we are extending this technology to whole human organs — transforming hours of viability into weeks, or months, however long is necessary — so that no donated organ is lost to logistics, and no patient dies waiting.
helping students and researchers turn research into ventures ↗
I co-founded Edventure, a pan-European startup incubator helping students and researchers turn bold ideas into real ventures. As founding director, I built and ran programs across the UK and Europe — from early pilots to partnerships with universities and, ultimately, Cancer Research UK, helping scientists and oncologists turn breakthroughs in cancer research into companies that save lives.
creating europe's biggest-ever student entrepreneurship conference ↗
In University, I started and co-hosted organised Europe's biggest-ever student entrepreneurship conference, featuring 47 founders, leaders, and operators from leading organizations.
A podcast interviewing founders, investors and other interesting peoplep.
innovating high-throughput drug discovery ↗
For my Neuroscience thesis at the University of Edinburgh, I designed and executed a high-throughput in vivo screen to evaluate 38 drug candidates for progressive multiple sclerosis (PMS) — a stage of the disease marked by neurodegeneration and currently lacking effective treatments. Using larval zebrafish, I assessed drug-induced toxicity across 18 physiological and morphological endpoints, generating over 23,000 datapoints. To overcome the interpretive bottlenecks of multi-endpoint screens, I developed a novel, modular toxicity index that captures cumulative, multidimensional toxicity as a single summary score — something existing indices (e.g. LD50 or LOADED) fail to do.
building a synthetically engineered biosensor for detection of water contaminants ↗
Representing the University of Edinburgh at iGEM, I co-developed a transcription-only, cell-free biosensing platform for rapid and cost-effective detection of water contaminants.
Our system replaced conventional GFP reporters with fluorescent RNA aptamers and incorporated isothermal amplification and basic logic processing via synthetic RNA transcription bubbles and T7 RNA polymerase.
personalizing boutique publishing ↗
In high school (in Germany), my brother and I built an online platform that let users create fully personalized print magazines — choosing their own articles, themes, and even the cover. Think: Spotify playlist meets boutique publishing. We partnered with major media brands like DIE ZEIT, handling everything from licensing to layout automation and on-demand printing.
The product found a niche with consumers, corporate clients, and cultural institutions, and was acquired in 2017 by a German publishing house modernizing its print strategy.
Get in touch